Company / Operating Cash Flow per Share
Rein Therapeutics, Inc. Operating Cash Flow per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.03
FY2025
5-year range
-$5.48 / -$0.47
FY2021-FY2025
Trend
+74.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share has fluctuated over the past 9 years, ranging from $-27.08 in FY2017 to $-0.47 in FY2021.
Based on SEC 10-K filings.
-1.03 in FY2025.
Improved from $-5.48 to $-1.03 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 74.6% year-over-year.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.03 | +74.6% |
| FY2024 | -$4.05 | +26.0% |
| FY2023 | -$5.48 | -4.4% |
| FY2022 | -$5.25 | -1022.1% |
| FY2021 | -$0.47 | +50.9% |
| FY2020 | -$0.95 | +49.7% |
| FY2019 | -$1.89 | -35.8% |
| FY2018 | -$1.39 | +94.9% |
| FY2017 | -$27.08 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026